Memantine Hydrochloride Tablet
Product Images NDC 71610-885

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71610-885). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0885 80)

Memantine Hydrochloride 10 mg oral tablets packaging label containing 180 tablets. The label includes storage instructions, manufacturer information (Ajanta Pharma USA Inc.), and the distributor (Aphena Pharma, Cookeville, TN). The label displays the NDC number 71610-885-80 and a barcode.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Memantine-figure1 (Memantine Figure1)

A line graph comparing mean change from baseline in ADCS-ADL scores over 28 weeks of treatment between placebo and Memantine Hydrochloride groups. The x-axis shows weeks of treatment (0, 4, 12, 28), and the y-axis shows mean change with error bars. Lines indicate clinical improvement and decline, with placebo showing greater decline than Memantine Hydrochloride over time.*

FDA Label Image

Memantine-figure3 (Memantine Figure3)

A line graph depicting mean (± SEM) change from baseline in SIB Score over 28 weeks of treatment comparing Memantine Hydrochloride and Placebo. The y-axis ranges from 4 to -12, indicating clinical improvement and decline, respectively. Two lines represent treatment groups showing differing trajectories over time with error bars at data points.*

FDA Label Image

Memantine-figure5 (Memantine Figure5)

A line graph showing change from baseline in ADCS-ADL score over 24 weeks of treatment comparing Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The graph includes mean ± SEM values and shows trends of clinical improvement or decline over time for both groups.*

FDA Label Image

Memantine-figure7 (Memantine Figure7)

A line graph showing mean (± SEM) change from baseline in SIB score over 24 weeks of treatment comparing Placebo/Donepezil versus Memantine Hydrochloride/Donepezil. The y-axis represents change in SIB score, with positive values indicating clinical improvement and negative values clinical decline. The x-axis shows weeks of treatment from 0 to 24. Memantine Hydrochloride/Donepezil shows an increase in SIB score peaking around week 12, then declining but remaining above baseline, while Placebo/Donepezil trends downward over time.*

FDA Label Image

Memantine_structure (Memantine Structure)

Chemical structure of Memantine Hydrochloride showing the molecular framework with amine (NH2) and hydrochloride (HCl) groups, along with methyl (CH3) substituents.*

FDA Label Image

Memantine-figure2 (Memantine Figure2)

A cumulative percentage of patients chart showing ADCS-ADL change from baseline on the x-axis and cumulative percentage on the y-axis. The chart compares two groups: placebo (represented with square markers) and memantine hydrochloride (represented with circle markers). The memantine hydrochloride group shows a higher cumulative percentage of patients with improved ADCS-ADL scores compared to the placebo group across the range.*

FDA Label Image

Memantine-figure4 (Memantine Figure4)

A line graph depicting the cumulative percentage of patients on the y-axis versus SIB (Severe Impairment Battery) change from baseline on the x-axis for Memantine Hydrochloride and placebo groups. Two curves are shown, one for placebo and one for Memantine Hydrochloride, illustrating patient response over a range of SIB changes.*

FDA Label Image

Memantine-figure6 (Memantine Figure6)

A cumulative percentage plot graph showing the comparison between Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The x-axis represents the ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients. The Memantine Hydrochloride/Donepezil group is represented by circles, and the Placebo/Donepezil group by squares.*

FDA Label Image

Memantine-figure8 (Memantine Figure8)

A cumulative percentage plot showing the proportion of patients versus change from baseline in SIB scores. Two treatment groups are represented: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, with the Memantine Hydrochloride/Donepezil curve indicating higher cumulative percentages at greater SIB score improvements.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.